
Generic name: Telpegfilgrastim Injection
Brand name: Pegneugen®
Dosage form: Injectable solution
Strengths:
PFS:
2.0mg (8.0×107U)/ 1.0mL solution in a single-dose prefilled syringe
1.0mg (4.0×107U)/ 0.5mL solution in a single-dose prefilled syringe
Vials:
2.0mg (8.0×107U)/ 1.0mL solution in a single-dose vial
1.0mg (4.0×107U)/ 0.5mL solution in a single-dose vial
Indications: Telpegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Telpegfilgrastim is not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Advantages:
Pegneugen® is a long-acting human granulocyte colony-stimulating factor with independent intellectual property rights, using a more stable and brand new PEG (40kD, Y-shape) to modify. Compared with other PEG-rhG-CSF launched in China, Pegneugen® has following advantages:
Efficiently and steadily increase leukocyte while reducing the potential risk of bone marrow over mobilization.